rs550499593

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The ENST00000507735.6(PALLD):​c.121C>G​(p.Pro41Ala) variant causes a missense change. The variant allele was found at a frequency of 0.000431 in 1,497,448 control chromosomes in the GnomAD database, including 7 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/17 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P41S) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.00068 ( 2 hom., cov: 32)
Exomes 𝑓: 0.00040 ( 5 hom. )

Consequence

PALLD
ENST00000507735.6 missense

Scores

2
12

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:3

Conservation

PhyloP100: 5.34

Publications

4 publications found
Variant links:
Genes affected
PALLD (HGNC:17068): (palladin, cytoskeletal associated protein) This gene encodes a cytoskeletal protein that is required for organizing the actin cytoskeleton. The protein is a component of actin-containing microfilaments, and it is involved in the control of cell shape, adhesion, and contraction. Polymorphisms in this gene are associated with a susceptibility to pancreatic cancer type 1, and also with a risk for myocardial infarction. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2009]
CBR4 (HGNC:25891): (carbonyl reductase 4) Enables several functions, including 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity; NADPH binding activity; and NADPH dehydrogenase (quinone) activity. Involved in fatty acid biosynthetic process; glycoside metabolic process; and protein tetramerization. Located in mitochondrial matrix. Part of oxidoreductase complex. [provided by Alliance of Genome Resources, Apr 2022]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0037773848).
BP6
Variant 4-168878012-C-G is Benign according to our data. Variant chr4-168878012-C-G is described in ClinVar as Benign. ClinVar VariationId is 135995.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population eas. GnomAd4 allele frequency = 0.000684 (104/152038) while in subpopulation EAS AF = 0.0194 (100/5158). AF 95% confidence interval is 0.0163. There are 2 homozygotes in GnomAd4. There are 64 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAd4 at 104 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PALLDNM_001166108.2 linkc.1965-12910C>G intron_variant Intron 10 of 21 ENST00000505667.6 NP_001159580.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PALLDENST00000505667.6 linkc.1965-12910C>G intron_variant Intron 10 of 21 1 NM_001166108.2 ENSP00000425556.1

Frequencies

GnomAD3 genomes
AF:
0.000691
AC:
105
AN:
151930
Hom.:
2
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000656
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.0195
Gnomad SAS
AF:
0.000620
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.00121
AC:
115
AN:
94802
AF XY:
0.00122
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000506
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0178
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.000347
GnomAD4 exome
AF:
0.000403
AC:
542
AN:
1345410
Hom.:
5
Cov.:
31
AF XY:
0.000432
AC XY:
287
AN XY:
663666
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
27380
American (AMR)
AF:
0.0000635
AC:
2
AN:
31504
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
23842
East Asian (EAS)
AF:
0.0149
AC:
460
AN:
30828
South Asian (SAS)
AF:
0.000672
AC:
51
AN:
75846
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
33226
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5264
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
1061368
Other (OTH)
AF:
0.000516
AC:
29
AN:
56152
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
34
68
101
135
169
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000684
AC:
104
AN:
152038
Hom.:
2
Cov.:
32
AF XY:
0.000861
AC XY:
64
AN XY:
74330
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41546
American (AMR)
AF:
0.0000655
AC:
1
AN:
15274
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.0194
AC:
100
AN:
5158
South Asian (SAS)
AF:
0.000621
AC:
3
AN:
4832
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10510
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
290
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
67936
Other (OTH)
AF:
0.00
AC:
0
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
5
11
16
22
27
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000189
Hom.:
1
Bravo
AF:
0.000722
ExAC
AF:
0.000420
AC:
8
Asia WGS
AF:
0.00440
AC:
15
AN:
3424

ClinVar

Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:1
Oct 29, 2024
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.

Pancreatic adenocarcinoma Benign:1
Jan 25, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PALLD-related disorder Benign:1
Dec 18, 2019
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.063
BayesDel_addAF
Benign
-0.42
T
BayesDel_noAF
Benign
-0.36
CADD
Benign
18
DANN
Benign
0.68
Eigen
Benign
-0.42
Eigen_PC
Benign
-0.40
FATHMM_MKL
Uncertain
0.85
D
LIST_S2
Benign
0.54
T
MetaRNN
Benign
0.0038
T
MetaSVM
Benign
-1.0
T
PhyloP100
5.3
PROVEAN
Benign
-0.91
N
REVEL
Benign
0.080
Sift
Benign
0.25
T
Sift4G
Uncertain
0.059
T
Vest4
0.11
ClinPred
0.019
T
GERP RS
3.8
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.8
Mutation Taster
=80/20
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs550499593; hg19: chr4-169799163; API